Custom vaccine targets ovarian Cancer's unique mutations
Disease control
Completed
This early-stage trial tested a personalized cancer vaccine called TG4050 in patients with ovarian, fallopian tube, or peritoneal cancer who were in remission after initial treatment. The main goal was to check if the vaccine was safe and well-tolerated. Researchers also looked f…
Phase: PHASE1 • Sponsor: Transgene • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC